The success of CAR-T therapy hinges upon the capability of T-cells to discern and eradicate tumor cells, a process that necessitates the activation of T-cells and the subsequent secretion of pivotal cytokines, notably gamma interferon (IFN-γ) [206]. The gene discussed is IFNG; the disease is neoplasm.